Ernexa Therapeutics Inc. Capitalized Computer Software, Impairments
Ernexa Therapeutics Inc. (ERNA) reported Capitalized Computer Software, Impairments of $248.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CapitalizedComputerSoftwareImpairments1 · last filed 2021-03-11
- Ernexa Therapeutics Inc. capitalized computer software, impairments for the quarter ending 2020-12-31 was $10.00K, a 97.99% decline year-over-year.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for the quarter ending 2020-06-30 was $100.00K.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for the quarter ending 2020-03-31 was $138.00K, a 13700.00% increase year-over-year.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for fiscal 2020 was $248.00K, a 54.91% decline from fiscal 2019.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for fiscal 2019 was $550.00K, a 2291.30% increase from fiscal 2018.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for fiscal 2018 was $23.00K, a 360.00% increase from fiscal 2017.
- Ernexa Therapeutics Inc. capitalized computer software, impairments for fiscal 2017 was $5.00K.
| Period end | Capitalized Computer Software, Impairments 3 month | Capitalized Computer Software, Impairments 3 month as first filed | Capitalized Computer Software, Impairments 6 month | Capitalized Computer Software, Impairments 6 month as first filed | Capitalized Computer Software, Impairments 9 month | Capitalized Computer Software, Impairments 9 month as first filed | Capitalized Computer Software, Impairments 12 month |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $10.00K derived: sum of 2 quarters · filed 2021-03-11 | $110.00K derived: sum of 3 quarters · filed 2021-03-11 | $248.00K 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $100.00K derived: sum of 2 quarters · filed 2020-11-13 | $238.00K 10-Q · filed 2020-11-13 | $736.00K derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-07 | $238.00K 10-Q · filed 2020-08-07 | $736.00K derived: sum of 3 quarters · filed 2021-03-11 | $787.00K derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2020-03-31 | $138.00K 10-Q · filed 2020-05-20 | $636.00K derived: sum of 2 quarters · filed 2021-03-11 | $687.00K derived: sum of 3 quarters · filed 2021-03-11 | $687.00K derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2019-12-31 | $498.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $549.00K derived: sum of 2 quarters · filed 2021-03-11 | $549.00K derived: sum of 3 quarters · filed 2021-03-11 | $550.00K 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $51.00K 10-Q · filed 2020-11-13 | $51.00K derived: sum of 2 quarters · filed 2020-11-13 | $52.00K 10-Q · filed 2020-11-13 | $42.00K 10-Q · filed 2019-11-01 | $22.00K derived: sum of 4 quarters · filed 2020-11-13 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.00K 10-Q · filed 2020-08-07 | $16.00K 10-Q · filed 2019-08-12 | -$29.00K derived: sum of 3 quarters · filed 2020-08-07 | $1.00K derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | $1.00K 10-Q · filed 2020-05-20 | $8.00K 10-Q · filed 2019-05-14 | -$29.00K derived: sum of 2 quarters · filed 2020-05-20 | $1.00K derived: sum of 3 quarters · filed 2020-05-20 | $22.00K derived: sum of 4 quarters · filed 2020-05-20 | ||
| 2018-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $0.00 derived: sum of 2 quarters · filed 2020-03-19 | $21.00K derived: sum of 3 quarters · filed 2020-03-19 | $23.00K 10-K · filed 2020-03-19 | |||
| 2018-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $51.00K derived: sum of 2 quarters · filed 2019-11-01 | $53.00K 10-Q · filed 2019-11-01 | $23.00K 10-Q · filed 2018-11-09 | $53.00K derived: sum of 4 quarters · filed 2019-11-01 | ||
| 2018-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $23.00K 10-Q · filed 2019-08-12 | $12.00K 10-Q · filed 2018-08-06 | $23.00K derived: sum of 3 quarters · filed 2019-08-12 | $24.00K derived: sum of 4 quarters · filed 2019-08-12 | ||
| 2018-03-31 | $2.00K 10-Q · filed 2019-05-14 | $2.00K derived: sum of 2 quarters · filed 2019-05-14 | $3.00K derived: sum of 3 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $1.00K derived: sum of 2 quarters · filed 2019-03-22 | $5.00K 10-K · filed 2019-03-22 | ||||
| 2017-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $5.00K 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $4.00K 10-Q · filed 2018-08-06 | ||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $0.00 derived: sum of 2 quarters · filed 2017-03-09 | $295.00K derived: sum of 3 quarters · filed 2017-03-09 | $295.00K 10-K · filed 2017-03-09 | |||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $295.00K derived: sum of 2 quarters · filed 2016-11-09 | $295.00K 10-Q · filed 2016-11-09 | ||||
| 2015-06-30 | $295.00K 10-Q · filed 2016-08-04 | $295.00K 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |